US 12,247,238 B2
Mogroside biocatalysis methods and products
Indra Prakash, Alpharetta, GA (US); Gil Ma, Atlanta, GA (US); Christopher Mercogliano, Atlanta, GA (US); Carol Hartley, Acton (AU); Matthew Alexander Wilding, Acton (AU); and Colin Scott, Acton (AU)
Assigned to The Coca-Cola Company, Atlanta, GA (US)
Appl. No. 17/434,234
Filed by The Coca-Cola Company, Atlanta, GA (US)
PCT Filed Feb. 26, 2020, PCT No. PCT/US2020/019972
§ 371(c)(1), (2) Date Aug. 26, 2021,
PCT Pub. No. WO2020/176668, PCT Pub. Date Sep. 3, 2020.
Claims priority of provisional application 62/810,553, filed on Feb. 26, 2019.
Prior Publication US 2022/0205010 A1, Jun. 30, 2022
Int. Cl. C12P 33/00 (2006.01); C07J 17/00 (2006.01)
CPC C12P 33/00 (2013.01) [C07J 17/005 (2013.01); C12Y 302/01023 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A modified beta-galactosidase enzyme comprising one or more mutations in the amino acid residues 200 through 212, wherein the beta-galactosidase enzyme having at least 50% identity to Aspergillus oryzae beta-galactosidase comprises one or more mutations selected from G204G, C205R, V208E or combinations thereof.